Cavity Boost Radiation Therapy vs. Observation in Cerebral Metastases After Complete Surgical Resection
- Conditions
- Cerebral MetastasesSurgery
- Interventions
- Radiation: Cavity boost radiation
- Registration Number
- NCT02887651
- Lead Sponsor
- Heinrich-Heine University, Duesseldorf
- Brief Summary
The purpose of this study is to determine whether a local fractionated radiation therapy achieves a better local tumor control after complete surgical metastases resection at 6 month as compared to observation alone. Further it should be evaluated if cognitive functioning and quality of life is similar in both groups.
- Detailed Description
The surgical resection of cerebral metastases as a key element in a multimodal therapeutic concept of brain metastatic patients is included in the common recommendations and international guidelines (level I evidence). These recommendations are based on a series of prospective, randomized and controlled studies which addressed the impact of the surgical metastases resection combined with a whole-brain radiation therapy (WBRT) in comparison to WBRT alone. Achieving local tumor control is the major goal of surgery and local tumor control rate after surgery alone has been addressed in few studies: A prospective, randomized American multicenter study revealed a local recurrence rate of 46% by median follow-up of 43 weeks for patients who underwent surgery alone without an adjuvant radiation therapy. Similarly, the 2-year local recurrence rate after metastases resection alone was 53.1% in a retrospective Korean study and 59% in the prospective, randomized and controlled EORTC 22952-26001 study.
In conclusion, standard surgery alone is not sufficient to achieve local control in about 50% of patients (evidence level I). Therefore, surgery of cerebral metastases is often followed by an adjuvant radiation therapy, which is an important part of a multi-modal therapy. Evidence for an additional adjuvant whole-brain radiation therapy (WBRT) after surgical resection was gained from a first prospective, randomized study in 1998: Patients treated by surgery followed by adjuvant WBRT had a significant lower local in-brain progression rate as compared to patients randomized to surgery alone (46% with a median follow-up of 48 weeks in the observation group vs. 10% with a median follow-up of 43 weeks). This result was recently confirmed by the EORTC 22952-26001 study: The 2-year local in-brain progression rate after surgical resection was reduced by a WBRT from 59% to 27%. But despite the lower local and also lower distant in-brain progression rate, the WBRT had no significant influence on the overall survival. The additional analysis of the quality of life data of the EORTC 22952-26001 study showed, that a WBRT negatively impacts the health-related quality of life with a statistically relevant and clinically significant impairment of the physical functioning (at 8 weeks), cognitive functioning and of the global health status. In conclusion, WBRT after surgery of cerebral metastases significantly reduces the incidence of local recurrences but has no impact on the overall survival and has a significant negative impact on the patient´s quality of life and cognitive function. Therefore, WBRT is not mandatory as adjuvant concept after surgical metastases resection and does not have an additional oncological impact in comparison to observation.
A local fractionated radiation therapy in analogy to the WBRT might achieve a similar local tumor control than observation alone but might be associated with an improved cognitive functioning as compared to WBRT. The purpose of this study is to determine whether a local fractionated radiation therapy achieves a better local tumor control after complete surgical metastases resection at 6 month as compared to observation alone. Further it should be evaluated if cognitive functioning and quality of life is similar in both groups.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 108
- histologically confirmed metastasis of carcinoma (except small cell carcinoma) or malignant melanoma
- 1-3 metastases in the preoperative MRI
- Karnofsky Performance Status (KPS) ≥ 70
- Age > / = 18 years
- Recursive partitioning analysis (RPA) 1-2
- life expectation ≥ 6 months
- no previous irradiation of the brain
- MRI examinations possible
- start of the radiation therapy possible within 6 weeks after surgery
- informed consent
- confirmation of residual tumor in the postoperative MRI
- dementia or disease of central nervous system with a higher risk or radiogenic toxicity
- contraindication for MRIs or lack of acceptance for a MRI
- Glasgow Coma Scale < 12
- Severe concomitant disease: severe cardiac, pulmonary, renal diseases with an increased risk of surgery and radiation
- previous therapeutic irradiation of the brain
- no histological confirmation of carcinoma metastases or malignant melanoma metastases
- cerebral metastases of small cell cancer, undifferentiate neuro-endocrine carcinoma, lymphoma, leucemia, sarcoma or germ cell tumor
- leptomeningeal carcinosis
- distance of the cerebral metastasis to the optic system or radiation sensible brain parts < 10 mm
- metastases of the brain stem, Di- or Mesencephalons, Pons oder Medulla oblongata
- bone marrow dysfunction
- contrast agent allergy
- pregnancy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description cavity boost radiation therapy Cavity boost radiation patients in the intervention arm receive an adjuvant local radiation therapy (cavity boost radiation therapy: 10 x 3 Gy ad 30 Gy; clinical target volume (CTV): resection cavity plus surrounding 5 mm; planning target volume (PTV): CTV + 1mm)
- Primary Outcome Measures
Name Time Method Local tumor control of resected metastases at 6 month 6 month Primary outcome measure is the local tumor control of resected metastases after local cavity boost radiation therapy or observation at 6 month
- Secondary Outcome Measures
Name Time Method Eortc qlq bn20 questionaire 3, 6, 9 12, 15, 18 month Secondary outcome measure is the patients quality of life at 3, 6, 9 12, 15, 18 month as assessed by the Eortc qlq bn20 questionaire
Mini-Mental State Examination (MMSE) 3, 6, 9 12, 15, 18 month Secondary outcome measure is the patients neurocognitive functioning at 3, 6, 9 12, 15 and 18 month as assessed by the MMSE
Test and Trail-Making Test (TMT) A & B 3, 6, 9 12, 15, 18 month Secondary outcome measure is the patients neurocognitive functioning at 3, 6, 9 12, 15 and 18 month as assessed by the Test and Trail-Making Test (TMT) A \& B
Distant tumor control of resected metastases at 6, 12 and 18 month 6, 12 and 18 month Secondary outcome measure is the distant tumor control at 6, 12 and 18 month
Eortc qlq c30 questionaire 3, 6, 9, 12, 15, 18 month Secondary outcome measure is the patients quality of life at 3, 6, 9, 12, 15 and 18 month as assessed by the Eortc qlq c30 questionaire
Hopkins Verbal Learning Test (HVLT) 3, 6, 9 12, 15, 18 month Secondary outcome measure is the patients neurocognitive functioning at 3, 6, 9, 12, 15 and 18 month as assessed by the Hopkins Verbal Learning Test (HVLT),
Local tumor control of resected metastases at 12 and 18 month 12, 18 month Secondary outcome measure is the local tumor control of resected metastases after local cavity boost radiation therapy or observation at 12 and 18 month
Incidence of leptomeningeal carcinosis 6, 12 and 18 month Secondary outcome measure is the incidence of a leptomeningeal carcinosis at 6, 12 and 18 month
Controlled Oral Word Association (COWA) 3, 6, 9 12, 15, 18 month Secondary outcome measure is the patients neurocognitive functioning at 3, 6, 9 12, 15 and 18 month as assessed by the Controlled Oral Word Association (COWA)
Trial Locations
- Locations (1)
Heinrich-Heine-University
🇩🇪Düsseldorf, NRW, Germany